GSK and ViiV Healthcare will share new data on its industry-leading infectious diseases pipeline and portfolio at the Infectious Disease Society of America’s IDWeek 2023 annual meeting.
Read More
Drug giant GlaxoSmithKline earned two victories in the ongoing battle to treat AIDS, one involving a patent settlement and the other securing FDA approval for a long-term HIV treatment from GSK-owned ViiV Healthcare.
Read More
The US Food and Drug Administration has approved the first injectable medication for pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV through sex, it announced Monday. And the drug has roots in North Carolina,
Read More
ViiV Healthcare, which has a major presence in RTP, has secured European Union approval for its once-a-month treatment of HIV, offering an alternative to daily care.
Read More
An injectable drug from ViiV Healthcare has proved to be much more effective in preventing HIV among women than a currently daily pill treatment, ViiV announced early Monday.
Read More
With all our attention focused on the COVID-19 coronavirus, it’s easy to forget that other viral outbreaks have wreaked havoc on the health of many Americans. Not at ViiV Healthcare.
Read More
A “major step” toward a possible cure for HIV with a technique that targets the virus as it lays dormant in people receiving treatment thus escaping being attacked by current therapy.
Read More
An analysis of Bandwidth.com, Supreme Court news on IBM, Red Hat and IBM back Google in dispute with Oracle, good news for ViiV and HIV treatment, and more in today’s tech roundup.
Read More
ViiV Healthcare, which has a large research and development operation in RTP, has filed for approval of an AIDS treatment that would help people infected with HIV who have developed a resistance or intolerance to other medications.
Read More
